Background and Purpose: Stroke-associated immunosuppression and inflammation are increasingly recognized as factors that trigger infections and thus, potentially influence the outcome after stroke. Several studies demonstrated that elevated neutrophil-to-lymphocyte ratio (NLR) is a significant predictor of adverse outcomes in patients with ischemic stroke. However, little is known about the impact of NLR on short-term mortality in intracerebral hemorrhage (ICH). Methods: This observational study included 855 consecutive ICH-patients. Patient demographics, clinical, laboratory, and in-hospital measures as well as neuroradiological data were retrieved from institutional databases. Functional 3-months-outcome was assessed and categorized as favorable (modified Rankin Scale [mRS] 0-3) and unfavorable (mRS 4-6). We (i) studied the natural course of NLR in ICH, (ii) analyzed parameters associated with NLR on admission (NLROA), and (iii) evaluated the clinical impact of NLR on mortality and functional outcome. Results: The median NLROA of the entire cohort was 4.66 and it remained stable during the entire hospital stay. Patients with NLR ≥4.66 showed significant associations with poorer neurological status (National Institute of Health Stroke Scale [NIHSS] 18 [9-32] vs. 10 [4-21]; p < 0.001), larger hematoma volume on admission (17.6 [6.9-47.7] vs. 10.6 [3.8-31.7] mL; p = 0.001), and more frequently unfavorable outcome (mRS 4-6 at 3 months: 317/427 [74.2%] vs. 275/428 [64.3%]; p = 0.002). Patients with an NLR under the 25th percentile (NLR <2.606) - compared to patients with NLR >2.606 - presented with a better clinical status (NIHSS 12 [5-21] vs. 15 [6-28]; p = 0.005), lower hematoma volumes on admission (10.6 [3.6-30.1] vs. 15.1 [5.7-42.3] mL; p = 0.004) and showed a better functional outcome (3 months mRS 0-3: 82/214 [38.3%] vs. 185/641 [28.9%]; p = 0.009). Patients associated with high NLR (≥8.508 = above 75th-percentile) showed the worst neurological status on admission (NIHSS 21 [12-32] vs. 12 [5-23]; p < 0.001), larger hematoma volumes (21.0 [8.6-48.8] vs. 12.2 [4.1-34.9] mL; p < 0.001), and higher proportions of unfavorable functional outcome at 3 months (mRS 4-6: 173/214 vs. 418/641; p < 0.001). Further, NLR was linked to more frequently occurring infectious complications (pneumonia 107/214 vs. 240/641; p = 0.001, sepsis: 78/214 vs. 116/641; p < 0.001), and increased c-reactive-protein levels on admission (p < 0.001; R2 = 0.064). Adjusting for the above-mentioned baseline confounders, multivariable logistic analyses revealed independent associations of NLROA with in-hospital mortality (OR 0.967, 95% CI 0.939-0.997; p = 0.029). Conclusions: NLR represents an independent parameter associated with increased mortality in ICH patients. Stroke physicians should focus intensely on patients with increased NLR, as these patients appear to represent a population at risk for infectious complications and increased short-mortality. Whether these patients with elevated NLR may benefit from a close monitoring and specially designed therapies should be investigated in future studies.

1.
Rueda-Clausen CF, Lopez-Jaramillo P, Luengas C, del Pilar Oubina M, Cachofeiro V, Lahera V: Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects. Mediators Inflamm 2009;2009:469169.
2.
Libby P: What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001;88:3J-6J.
3.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
4.
Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M, Costantino T: Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 2013;11:55-59.
5.
Wang F, Hu S, Ding Y, Ju X, Wang L, Lu Q, Wu X: Neutrophil-to-lymphocyte ratio and 30-day mortality in patients with acute intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2016;25:182-187.
6.
Lattanzi S, Cagnetti C, Provinciali L, Silvestrini M: Neutrophil-to-lymphocyte ratio predicts the outcome of acute intracerebral hemorrhage. Stroke 2016;47:1654-1657.
7.
Walsh KB, Sekar P, Langefeld CD, Moomaw CJ, Elkind MS, Boehme AK, James ML, Osborne J, Sheth KN, Woo D, Adeoye O: Monocyte count and 30-day case fatality in intracerebral hemorrhage. Stroke 2015;46:2302-2304.
8.
Yang B, Wang S, Yu S, Chen Y, Li L, Zhang H, Zhao Y: C1q/tumor necrosis factor-related protein 3 inhibits oxidative stress during intracerebral hemorrhage via PKA signaling. Brain Res 2017;1657:176-184.
9.
Chen-Roetling J, Regan RF: Targeting the Nrf2-heme oxygenase-1 axis after intracerebral hemorrhage. Curr Pharm Des 2016, Epub ahead of print.
10.
Tao X, Xie L, Duan C, Dai S, Ren J, Yan Y, Shen J, Lu H, Ge J: Up-regulation of interferon regulatory factor 3 involves in neuronal apoptosis after intracerebral hemorrhage in adult rats. Neurochem Res 2016;41:2937-2947.
11.
Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Napankangas J, Makela J, Karttunen TJ, Tuomisto A, Makinen MJ: Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 2012;107:1729-1736.
12.
Tapia-Perez JH, Karagianis D, Zilke R, Koufuglou V, Bondar I, Schneider T: Assessment of systemic cellular inflammatory response after spontaneous intracerebral hemorrhage. Clin Neurol Neurosurg 2016;150:72-79.
13.
Zahorec R: Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14.
14.
Gokhan S, Ozhasenekler A, Mansur Durgun H, Akil E, Ustundag M, Orak M: Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. Eur Rev Med Pharmacol Sci 2013;17:653-657.
15.
Gibson PH, Cuthbertson BH, Croal BL, Rae D, El-Shafei H, Gibson G, Jeffrey RR, Buchan KG, Hillis GS: Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010;105:186-191.
16.
Tao C, Hu X, Wang J, Ma J, Li H, You C: Admission neutrophil count and neutrophil to lymphocyte ratio predict 90-day outcome in intracerebral hemorrhage. Biomark Med 2017;11:33-42.
17.
Tao C, Wang J, Hu X, Ma J, Li H, You C: Clinical value of neutrophil to lymphocyte and platelet to lymphocyte ratio after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2016, Epub ahead of print.
18.
Yu S, Arima H, Heeley E, Delcourt C, Krause M, Peng B, Yang J, Wu G, Chen X, Chalmers J, Anderson CS: White blood cell count and clinical outcomes after intracerebral hemorrhage: the INTERACT2 trial. J Neurol Sci 2016;361:112-116.
19.
Morotti A, Phuah CL, Anderson CD, Jessel MJ, Schwab K, Ayres AM, Pezzini A, Padovani A, Gurol ME, Viswanathan A, Greenberg SM, Goldstein JN, Rosand J: Leukocyte count and intracerebral hemorrhage expansion. Stroke 2016;47:1473-1478.
20.
Kuramatsu JB, Gerner ST, Lucking H, Kloska SP, Schellinger PD, Kohrmann M, Huttner HB: Anemia is an independent prognostic factor in intracerebral hemorrhage: an observational cohort study. Crit Care 2013;17:R148.
21.
Kuramatsu JB, Bobinger T, Volbers B, Staykov D, Lucking H, Kloska SP, Kohrmann M, Huttner HB: Hyponatremia is an independent predictor of in-hospital mortality in spontaneous intracerebral hemorrhage. Stroke 2014;45:1285-1291.
22.
Tejerina E, Esteban A, Fernandez-Segoviano P, Frutos-Vivar F, Aramburu J, Ballesteros D, Rodriguez-Barbero JM: Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings. J Crit Care 2010;25:62-68.
23.
Muckart DJ, Bhagwanjee S: American college of chest physicians/society of critical care medicine consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 1997;25:1789-1795.
24.
Wilson ML, Gaido L: Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004;38:1150-1158.
25.
Wang X, Arima H, Al-Shahi Salman R, Woodward M, Heeley E, Stapf C, Lavados PM, Robinson T, Huang Y, Wang J, Delcourt C, Anderson CS: Rapid blood pressure lowering according to recovery at different time intervals after acute intracerebral hemorrhage: pooled analysis of the INTERACT studies. Cerebrovasc Dis 2015;39:242-248.
26.
Azab B, Camacho-Rivera M, Taioli E: Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One 2014;9:e112361.
27.
Rankin J: Cerebral vascular accidents in patients over the age of 60. I. General considerations. Scott Med J 1957;2:127-136.
28.
Burgess RE, Warach S, Schaewe TJ, Copenhaver BR, Alger JR, Vespa P, Martin N, Saver JL, Kidwell CS: Development and validation of a simple conversion model for comparison of intracerebral hemorrhage volumes measured on CT and gradient recalled echo MRI. Stroke 2008;39:2017-2020.
29.
Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J: The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996;27:1304-1305.
30.
Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28:1-5.
31.
Graeb DA, Robertson WD, Lapointe JS, Nugent RA, Harrison PB: Computed tomographic diagnosis of intraventricular hemorrhage. Etiology and prognosis. Radiology 1982;143:91-96.
32.
Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, Castillo J: Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004;63:461-467.
33.
Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G, Liesz A, Veltkamp R: Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 2009;40:3226-3232.
34.
Liesz A, Ruger H, Purrucker J, Zorn M, Dalpke A, Mohlenbruch M, Englert S, Nawroth PP, Veltkamp R: Stress mediators and immune dysfunction in patients with acute cerebrovascular diseases. PLoS One 2013;8:e74839.
35.
Sato S, Arima H, Heeley E, Hirakawa Y, Delcourt C, Lindley RI, Robinson T, Huang Y, Morgenstern L, Stapf C, Wang J, Chalmers J, Anderson CS: Off-hour admission and outcomes in patients with acute intracerebral hemorrhage in the INTERACT2 trial. Cerebrovasc Dis 2015;40:114-120.
36.
Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y: Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013;58:58-64.
37.
Montecucco F, Liberale L, Bonaventura A, Vecchie A, Dallegri F, Carbone F: The role of inflammation in cardiovascular outcome. Curr Atheroscler Rep 2017;19:11.
38.
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ: The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-230.
39.
Sansing LH, Harris TH, Kasner SE, Hunter CA, Kariko K: Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage. Acta Neurochir Suppl 2011;111:173-178.
40.
Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U: Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005;6:775-786.
41.
Naess A, Nilssen SS, Mo R, Eide GE, Sjursen H: Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever. Infection 2016, Epub ahead of print.
42.
Chu S, Xu F, Su Y, Chen H, Cheng X: Cerebral amyloid angiopathy (CAA)-related inflammation: comparison of inflammatory CAA and amyloid-β-related angiitis. J Alzheimers Dis 2016;51:525-532.
43.
Salvarani C, Morris JM, Giannini C, Brown RD Jr, Christianson T, Hunder GG: Imaging findings of cerebral amyloid angiopathy, Aβ-related angiitis (ABRA), and cerebral amyloid angiopathy-related inflammation: a single-institution 25-year experience. Medicine (Baltimore) 2016;95:e3613.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.